YOLFTbeta
Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA · XETRA · Healthcare / Biotechnology

2.09EUR+0.05 (+2.45%)

Price History

Full chart

Market Stats

Previous Close2.04
Open2.10
Day Range2.05 – 2.14
52-Week Range2.30 – 3.34
Volume224
Market Cap109.94M
P/E (TTM)0.00
Forward P/E129.87
EPS-0.71
Dividend Yield0.00%
Beta0.77
50-Day Avg2.52
200-Day Avg2.74

About

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia, and Antibody Drug Conjugates (ADCs). The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Dongzhou Liu Ph.D.
  • Employees41
  • HeadquartersGregor-Mendel-Strasse 22, Ladenburg, Germany, 68526, Germany
  • Websitehttps://heidelberg-pharma.com

Leadership

  • Dr. Dongzhou Liu Ph.D.CEO & Chairman of Executive Management Board
  • Mr. Peter WillingerChief Financial Officer
  • Dr. Jorg KemkowskiChief Operating Officer
  • Sylvia WimmerSenior Director of Corporate Communications
  • Dr. George Octavian BadescuChief Business Officer

Financials

Income Statement

Currency: EUR2006-11-302007-11-302008-11-302009-11-302010-11-302011-11-302012-11-302013-11-302014-11-302015-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Total Revenue---10.00M-9.88M17.84M13.32M3.60M2.28M1.36M1.90M3.67M7.31M8.49M2.90M18.51M9.86M6.85M1.46M
Growth (%)------+80.63%-25.36%-72.99%-36.50%-40.37%+39.50%+93.05%+99.26%+16.13%-65.81%+537.89%-46.75%-30.53%-78.72%
Cost of Revenue-----4.17M6.75M3.68M1.35M1.14M809.06K956.66K2.21M3.74M5.60M4.71M4.68M3.25M1.78M2.64M
Gross Profit---10.00M-5.71M11.10M9.64M2.24M1.14M552.94K943.34K1.46M3.57M2.89M-1.81M13.83M6.61M5.07M-1.19M
Gross Margin---100.00%-57.83%62.19%72.38%62.34%50.09%40.60%49.65%39.80%48.85%34.03%-62.35%74.72%67.01%74.01%-81.41%
Operating Expense---22.86M-19.10M20.01M14.60M7.82M7.66M6.91M11.70M13.13M13.93M21.45M23.33M31.02M27.82M25.73M46.26M
Operating Income-18.25M-23.93M-21.39M-12.86M-23.11M-13.38M-8.91M-4.96M-5.58M-6.52M-6.36M-10.75M-11.67M-10.36M-18.56M-25.14M-17.18M-21.21M-20.67M-47.44M
Operating Margin----128.64%--135.49%-49.94%-37.27%-155.03%-285.31%-467.04%-565.93%-318.21%-141.80%-218.71%-866.07%-92.80%-215.13%-301.72%-3255.36%
EBITDA-17.52M-21.95M-20.17M-12.47M-22.87M-12.86M-8.21M-3.16M-5.09M-6.20M-6.08M-10.35M-11.72M-9.60M-17.55M-24.35M-16.19M-18.71M-14.48M-44.63M
EBITDA Margin----124.69%--130.19%-46.01%-23.76%-141.42%-271.50%-446.40%-544.54%-319.48%-131.29%-206.77%-838.88%-87.45%-189.74%-211.36%-3062.01%
Net Income---20.45M-12.73M-23.09M-13.93M-9.39M-5.04M-5.70M-6.55M-6.39M-10.97M-11.67M-10.15M-18.37M-26.14M-19.70M-20.35M-19.38M-42.28M
Net Income Margin----127.29%--140.99%-52.64%-37.85%-158.49%-286.85%-469.09%-577.38%-318.21%-138.84%-216.47%-900.60%-106.42%-206.38%-282.98%-2901.15%
R&D10.67M16.23M20.16M21.82M19.70M15.64M12.78M12.43M5.57M4.44M6.12M9.32M10.68M10.94M18.29M18.75M26.38M28.07M21.84M38.78M
R&D as % of Total Revenue---218.23%-158.36%71.63%93.32%154.91%194.60%449.27%490.69%291.14%149.70%215.45%646.03%142.47%284.77%318.92%2660.82%
Interest Expense0011.62K7.60K5.48K547.62K508.50K160.24K118.07K54520.00K218.00K0220.92K13.56K494.00K840.00K761.60K141.50K4.91K
Interest Expense % of Total Revenue---0.08%-5.54%2.85%1.20%3.28%0.02%1.47%11.47%0.00%3.02%0.16%17.02%4.54%7.72%2.07%0.34%

Balance Sheet

Currency: EUR2006-11-302007-11-302008-11-302009-11-302010-11-302011-11-302012-11-302013-11-302014-11-302015-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Total Assets59.71M37.63M15.33M12.01M5.59M20.81M37.72M22.31M15.03M12.10M15.24M41.49M31.19M22.99M19.61M21.73M100.58M70.35M60.72M38.14M
Total Liabilities11.99M11.68M9.54M8.97M6.89M25.34M17.80M7.36M3.15M2.62M5.49M4.47M5.31M6.70M6.73M15.03M33.94M21.01M29.85M49.05M
Total Equity47.72M25.95M5.79M3.04M-1.30M-4.52M19.92M14.95M11.88M9.48M9.76M37.02M25.89M16.29M12.88M6.70M66.64M49.34M30.87M-10.92M
Cash56.71M18.80M12.14M3.41M1.94M3.42M23.36M8.92M2.20M1.31M4.57M30.38M19.44M9.88M4.98M6.14M81.33M43.44M29.42M14.98M
Total Debt--15.36K-57.99K11.02M2.98M2.75M77.48K-3.75M---202.68K10.63M15.98M5.83M21.97M1.16M
Net Debt-56.71M-18.80M-12.12M-3.41M-1.89M7.60M-20.39M-6.17M-2.12M-1.31M-826.38K-30.38M-19.44M-9.88M-4.78M4.49M-65.35M-37.61M-7.45M-13.81M

Cash Flow

Currency: EUR2006-11-302007-11-302008-11-302009-11-302010-11-302011-11-302012-11-302013-11-302014-11-302015-11-302016-11-302017-11-302018-11-302019-11-302020-11-302021-11-302022-11-302023-11-302024-11-302025-11-30
Operating Cash Flow-14.62M-20.97M-21.50M-18.45M-19.24M-9.00M-5.11M-14.45M-6.62M-4.80M-6.53M-7.94M-9.98M-8.56M-17.89M-26.61M-8.86M-33.67M-29.59M-31.60M
Investing Cash Flow157.02K-14.28M14.93M-71.20K-475.54K582.58K-244.44K-172.17K-195.80K-207.03K-537.87K-416.07K-1.00M-975.80K-1.29M-1.40M-597.57K5.85M-449.13K-135.05K
Financing Cash Flow51.78M-959.94K-88.89K9.79M18.24M9.82M25.34M-224.32K-38.44K4.10M10.33M34.18M14.29M-114.29M29.17M84.00M-10.05M16.08M18.35M
Capital Expenditure0067.74K71.19K49.88K302.74K244.44K172.17K195.80K207.03K537.87K416.07K1.00M963.20K1.43M1.39M612.93K959.85K456.02K128.66K
Free Cash Flow-14.62M-20.97M-21.57M-18.52M-19.29M-9.30M-5.35M-14.62M-6.82M-5.00M-7.07M-8.36M-10.98M-9.52M-19.33M-28.00M-9.48M-34.63M-30.04M-31.73M
FCF to OCF100.00%100.00%100.32%100.39%100.26%103.36%104.79%101.19%102.96%104.32%108.23%105.24%110.03%111.26%108.02%105.22%106.91%102.85%101.54%100.41%

Earnings

Report DateApr 13, 2007Jul 12, 2007Oct 11, 2007Nov 30, 2007Apr 10, 2008Jul 14, 2008Oct 13, 2008Nov 30, 2008Apr 8, 2009Jul 14, 2009Oct 13, 2009Feb 24, 2010Apr 14, 2010Jul 14, 2010Oct 13, 2010Feb 22, 2011Apr 13, 2011Jul 14, 2011Oct 13, 2011Apr 12, 2012Jul 12, 2012Oct 12, 2012Feb 27, 2013Apr 11, 2013Jul 11, 2013Oct 10, 2013Mar 31, 2014Jul 15, 2014Oct 15, 2014Apr 14, 2015Jul 14, 2015Oct 15, 2015Apr 14, 2016Jul 14, 2016Oct 13, 2016Mar 30, 2017Jul 13, 2017Oct 9, 2017Mar 21, 2018Jul 12, 2018Oct 11, 2018Mar 21, 2019Jul 11, 2019Oct 10, 2019Mar 19, 2020Jul 9, 2020Oct 8, 2020Apr 20, 2021Jul 8, 2021Oct 7, 2021Mar 24, 2022Jul 12, 2022Oct 13, 2022Apr 13, 2023Jul 13, 2023Oct 12, 2023Apr 25, 2024Jul 12, 2024Oct 10, 2024Jan 29, 2025Apr 24, 2025Jul 10, 2025Oct 9, 2025Jan 28, 2026Mar 26, 2026May 31, 2026
EPS Estimate-2.56-2.33-2.06--2.22-2.29-1.91--1.64-1.41-0.27-1.83--1.68-1.30--1.221.19--0.27------------------0.20---0.15---------------------0.000.000.00-
EPS Actual-1.57-1.83-1.68-1.60-1.57-2.06-1.68-1.00-1.83-1.30-0.19-0.50-1.24-1.49-1.30-1.19-1.22-0.84-0.45-0.42-0.49-0.27-0.19-0.24-0.19-0.05-0.35-0.180.31-0.13-0.09-0.17-0.10-0.11-0.13-0.14-0.17-0.22-0.24-0.14-0.06-0.14-0.04-0.06-0.160.17-0.10-0.19-0.22-0.17-0.21-0.04-0.14-0.14-0.200.00-0.10-0.09-0.12-0.11-0.13-0.14-0.18-0.45-0.090.02
Surprise38.67%21.46%18.45%-29.28%10.04%12.04%--11.59%7.80%29.63%72.68%-11.31%0.00%-0.00%-170.59%--55.56%------------------10.00%--60.00%-------------------------
TimingPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-After-hoursAfter-hours-After-hoursAfter-hours-After-hours-----------------After-hours--Pre-market----------Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market----

Key Statistics & Ratios

Market Cap109.94M
Enterprise Value94.88M
Trailing P/E0.00
Forward P/E129.87
PEG Ratio5.46
Price / Sales14.77
Price / Book13.02
EPS-0.71
Book Value-0.304
Revenue (TTM)7.45M
Gross Profit (TTM)6.51M
EBITDA-36.85M
Profit Margin0.00%
Operating Margin3.32%
Return on Equity-1539.85%
Return on Assets-42.58%
Shares Outstanding46.78M
Shares Float9.97M
Beta0.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 18, 20141:4